Background/Aims Studies in animals suggest a physiological role for glucagon-like peptide-1-(7–36)-amide (GLP-1) in regulating satiety. The role of GLP-1 in regulating food intake in man has, however, ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within 1 year, but those without type 2 diabetes had higher ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

With glucagon-like peptide 1 (GLP-1) agonists now close to inducing weight loss at levels only seen before through surgical intervention, obesity specialists say patients on these drugs are ...

4 China Medical University College of Chinese Medicine, Taichung, Taiwan Background Clinical studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RA) can have beneficial effects on ...

Objective To fulfil an unmet therapeutic need for treating type 2 diabetes by developing an innovative oral drug delivery nanosystem increasing the production of glucagon-like peptide-1 (GLP-1) and ...

For patients who have been paying for Ozempic or other glucagon-like peptide-1 medications, there may be another beneficial development: On December 23, the U.S. Food and Drug Administration (FDA) ...

These drugs, called glucagon-like peptide-1 receptor agonists (GLP-1 RAs), work in several different ways to help people lose weight, gain control over their blood sugar levels, and improve their ...